Meeting
2014 ASCO Annual Meeting
Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts.
Authors
Dirkje Willemien Sommeijer
NHMRC Clinical Trials Centre, Sydney; Flevohospital, Almere; Academic Medical Centre, Amsterdam, Netherlands
Dirkje Willemien Sommeijer , Qian Shi , Everardo D. Saad , Elisabeth Coart , Marc E. Buyse , Tomasz Burzykowski , Jeffrey P. Meyers , Tim Maughan , Richard A. Adams , Matthew T. Seymour , Leonard Saltz , Richard M. Goldberg , Jean-Yves Douillard , Hans-Joachim Schmoll , Cornelis J. A. Punt , Christophe Tournigand , Benoist Chibaudel , Aimery De Gramont , Daniel J. Sargent , John Raymond Zalcberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3538)
DOI
10.1200/jco.2014.32.15_suppl.3538
Abstract #
3538
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database.
First Author: Everardo D. Saad
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2014 Gastrointestinal Cancers Symposium
Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.
First Author: Stefan Kubicka